Peptide · Research Monograph · 28-residue neuropeptide studied at VPAC1 and VPAC2 receptors

VIP

Vasoactive Intestinal Peptide Studies

VIP is a 28-amino acid neuropeptide of the secretin family, studied at the VPAC1 and VPAC2 receptors. Published research covers smooth-muscle relaxation, immunomodulation and neuroprotection endpoints, with cyclic AMP signalling as the principal characterised second messenger. For laboratory research use only.

Length
28 residues
Size
10mg
Form
Lyophilized powder

For laboratory research use only - not for human or animal use

VIP vial from the Eon Peptides research catalog
VIP · 10mg · catalog photograph
Available in the Eon catalog - VIP from $95.00

Molecular data

Sequence length28 residues
Physical formLyophilized powder
Available sizes10mg

How it works

  1. Receptor

    VPAC1 and VPAC2 Signalling

    VIP binds the class B G-protein-coupled receptors VPAC1 and VPAC2. Adenylate cyclase activation and cyclic AMP accumulation are the principal characterised readouts.

    • VPAC1 / VPAC2 engagement
    • Adenylate cyclase activation
    • Cyclic AMP accumulation
  2. Physiology

    Smooth Muscle Relaxation

    Smooth-muscle relaxation endpoints are long characterised for VIP across vascular and gastrointestinal tissue preparations.

    • Vascular preparations
    • Gastrointestinal tissue
    • Relaxation endpoints
  3. Immunology

    Immunomodulatory Endpoints

    VIP is studied as an endogenous anti-inflammatory mediator, with cytokine-profile shifts measured in immune cell culture.

    • Cytokine profile shifts
    • Immune cell culture
    • Anti-inflammatory mediator

What the research shows

  1. Physiology

    Smooth Muscle Models

    Relaxation endpoints are characterised in vascular and gastrointestinal tissue preparations.

  2. Immunology

    Immunomodulation

    Cytokine-profile endpoints are measured in immune cell culture.

  3. Neuroscience

    Neuroprotection Models

    VIP appears in neuroprotection literature alongside its receptor-signalling characterisation.

  4. Analytical

    Reference Peptide

    Used as a characterised VPAC-receptor agonist reference in assay development.

Specification

Chemical NameVIP (vasoactive intestinal peptide)
Length28 amino acids
FamilySecretin peptide family
Content10 mg per vial
Receptor TargetsVPAC1, VPAC2 (class B GPCRs)
Second MessengerCyclic AMP
FormLyophilized powder
Purity≥99% by HPLC
SolubilityWater-soluble
Storage-20°C, protected from light
ClassificationResearch use only

Frequently asked questions

What receptors does VIP act on?

VPAC1 and VPAC2, both class B G-protein-coupled receptors. Adenylate cyclase activation and cyclic AMP accumulation are the principal characterised readouts.

Is a molecular weight listed?

The molecular weight will be published here from the lot's Certificate of Analysis rather than quoted from a secondary source.

Is VIP related to PACAP?

Yes. Both belong to the secretin peptide family and share the VPAC receptors, which is why they are frequently studied together.

What purity is documented?

Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.

How is it stored?

Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.

For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.